



Biotech Daily

Thursday July 4, 2019

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: IMPEDIMED UP 17%; OSPREY DOWN 7%**
- * **MEDLAB Q4 REVENUE UP 135% TO \$3m**
- * **CELLMID EXPECTS Q4 RECORD REVENUE OF \$2.45m**
- * **ELIXINOL APPOINTS MEDVEC GERMAN DISTRIBUTOR**
- * **MEDIBIO REQUESTS 'CAPITAL RAISING' TRADING HALT**
- * **THC REQUESTS MARIJUANA 'MANUFACTURE LICENCE' HALT**
- * **AUSTRALIAN ETHICAL BELOW 5% OF MACH7**
- * **PLATINUM INCREASES, DILUTED TO 8.5% OF ADALTA**
- * **HISHENK TAKES 17% OF KAZIA**
- * **JIMMY THOMAS, IVY PONNIAH TAKE 5% OF GENETIC TECHNOLOGIES**
- * **JIMMY THOMAS, IVY PONNIAH TAKE 5% OF STEMCELL UNITED**

MARKET REPORT

The Australian stock market was up 0.49 percent on Thursday July 4, 2019, with the ASX200 up 32.5 points to 6,718.0 points. Twenty-one of the Biotech Daily Top 40 stocks were up, 12 fell, six traded unchanged and one was untraded.

Impedimed was the best, up two cents or 16.7 percent to 14 cents, with 2.2 million shares traded. Actinogen climbed 10 percent; Imugene was up 7.1 percent; Proteomics rose 6.1 percent; Dimerix improved 5.3 percent; Opthea, Prescient and Resonance were up more than four percent; Kazia was up 3.9 percent; Antisense, Genetic Signatures, Medical Developments and Universal Biosensors rose more than two percent; Avita, Benitec, CSL, Mesoblast, Polynovo and Telix were up more than one percent; with Cyclopharm, Cynata and Neuren up by less the one percent.

Osprey led the falls, down half a cent or 6.85 percent to 6.8 cents, with 712,150 shares traded. Orthocell fell 4.1 percent; Alterity (Prana) lost 3.3 percent; Immutep and Starpharma shed two percent or more; Clinuvel, Ellex and Oncosil were down more than one percent; with Cochlear, Nanosonics, Paradigm, Pro Medicus, Resmed and Volpara down by less than one percent.

[MEDLAB CLINICAL](#)

Medlab says revenue for the three months to June 30, 2019 was up 135 percent to more than \$3 million and year on year growth was more than 50 percent.

Medlab said the revenue was from commercialization of its food additives and marijuana-based products.

The company said the figures excluded research and development tax incentives and discounts on products

Medlab said that its product range could be found in more than 3,000 Australian pharmacies.

Medlab was up two cents or 5.7 percent to 37 cents with 1.7 million shares traded.

[CELLMID](#)

Cellmid says that sales of its hair growth products for the three months to June 30, 2019 are expected be a record \$2.45 million, the company's highest quarterly result.

Cellmid said a sales promotion on a Japanese television shopping channel delivered sales revenue of \$1.14 million.

Cellmid was up four cents or 19.5 percent to 24.5 cents.

[ELIXINOL GLOBAL](#)

Elixinol says it has an exclusive distribution agreement with the Neckargemünd, Germany-based Medvec International GmbH for its hemp products in Germany.

Elixinol said Medvec would sell its products to pharmacies and "para pharmacies" for "an initial graduated period", with an extension for a further three years.

The company said the agreement was based on minimum annual sales and Medvec would have an exclusive contract in Germany and co-exclusively in Austria and Switzerland.

Elixinol chief executive officer Paul Benhaim said "the distribution agreement with Medvec allows Elixinol to significantly expand its presence in Germany, the largest pharmacy market in Europe, as well as Austria and Switzerland".

Elixinol was up 18 cents or 4.9 percent to \$3.85 with 1.2 million shares traded.

[MEDIBIO](#)

Medibio has requested a trading halt "pending an announcement ... in relation to a capital raising".

Trading will resume on July 9, 2019 or on an earlier announcement.

Medibio last traded last traded at 1.9 cents with 13.8 million shares traded.

[THC GLOBAL GROUP \(FORMERLY THE HYDROPONICS COMPANY\)](#)

THC says it has requested a trading halt "pending an announcement with respect to the grant of a [marijuana] manufacture licence by the Office of Drug Control".

Trading will resume on July 9, 2019 or on an earlier announcement.

THC last traded down half a cent or 1.2 percent to 42 cents.

KAZIA THERAPEUTICS

Hishenk Pty Limited says it has increased its substantial shareholding in Kazia from 6,685,142 shares (13.8%) to 10,835,000 (17.4%).

The Artarmon, Sydney-based Hishenk said that between October 3 and 26, 2018, it and its related parties, bought 662,981 shares on market for \$301,468 or 45.5 cents a share and sold 9,000 shares for \$3,420 or 38 cents a share.

Hishenk said it participated in the October \$3.4 million placement, acquiring 1,307,895 shares for \$497,000 or 38 cents a share and 350,000 shares for \$133,000 or 38 cents a share (BD: Oct 18, 2018).

Hishenk said that on June 26, 2019, it entered into a call option deed between Willoughby Capital and Kilinwata Investments, acting as trustee for Life Sciences Portfolio Managers Trust, for 1,844,000 options, which if exercised would cost \$610,133 or 33.1 cents an option.

The company said the related parties were MNA Family Holdings, Hishenk and Willoughby Capital acting for Willoughby Capital Trust, with the signatory Stephen Abolakian who said Michael Abolakian was a shareholder of Willoughby Capital and Hishenk.

Kazia was up 1.5 cents or 3.9 percent to 40 cents.

MACH7 TECHNOLOGIES

Australian Ethical Investment says it has ceased its substantial shareholding in Mach7, selling 1,115,957 shares for \$582,496 or 52.2 cents a share.

In April, Australian Ethical said it became substantial with 8,027,379 shares or 5.43 percent, buying the shares for an average of 19.85 cents a share (BD: Apr 9, 2019).

Biotech Daily calculates that Australian Ethical retains 6,911,422 shares or 4.65 percent of Mach7.

Mach7 was unchanged at 54 cents with 1.2 million shares traded.

ADALTA

Platinum Investment Management says it has increased its substantial holding in Adalta and been diluted from 11,333,400 shares (9.81%) to 14,000,067 shares (8.52%).

The Sydney-based Platinum said it bought the 2,666,667 shares for \$400,000, or 15 cents a share on May 22 and 23, 2019.

Earlier this month, Adalta said it had raised \$5 million in a placement and \$2 million in a rights issue at 15 cents a share (BD: May 23, Jun 14, 2018).

Adalta was up half a cent or 3.6 percent to 14.5 cents.

GENETIC TECHNOLOGIES

Jimmy Thomas and Ivy Ruth Ponniah say they have become substantial shareholders in Genetic Technologies with 141,941,607 shares or 5.2 percent.

The Brisbane, Queensland-based Mr Thomas and Ms Ponniah said that between April 8 and July 3, 2019 they bought 141,941,607 shares for \$1,012,775 or 0.7 cents a share.

Genetic Technologies was unchanged at 0.7 cents with 1.8 million shares traded.

STEMCELL UNITED

Jimmy Thomas and Ivy Ruth Ponniah say they have become substantial shareholders in Stemcell with 32,195,449 shares or five percent.

The Brisbane, Queensland-based Mr Thomas and Ms Ponniah said that between October 25, 2018 and July 1, 2019 they bought 32,195,449 shares for \$679,478 or an average price of 2.1 cents a share.

Stemcell was unchanged at 1.6 cents.